Zeitschriftenaufsatz
|
2018
PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact
Autor:in
Grubmueller, Bernhard; Baltzer, Pascal; Hartenbach, Sabrina; D'andrea, David; Helbich, Thomas H.; Haug, Alexander; Goldner, Gregor; Wadsak, Wolfgang; Pfaff, S.; Mitterhauser, Markus; Balber, Theresa; Berroteran-Infante, Neydher; Grahovac, Marko; Babich, John; Seitz, Christian M.; Kramer, Gero; Susani, M.; Mazal, Peter; Kenner, Lukas; Shariat, Shahrokh F.; Hacker, Marcus; Hartenbach, Markus
Publikationen als Autor:in / Herausgeber:in der Vetmeduni
Journal
Abstrakt
Purpose: Primary staging of prostate cancer relies on modalities, which are limited. We evaluate simultaneous [Ga-68]Ga-PSMA-11 PET (PSMA-PET)/MRI as a new diagnostic method for primary tumor-node-metastasis staging compared with histology and its impact on therapeutic decisions.
Experimental Design: We investigated 122 patients with PSMA-PET/MRI prior to planned radical prostatectomy (RP). Primary endpoint was the accuracy of PSMA-PET/MRI in tumor staging as compared with staging-relevant histology. In addition, a multidisciplinary team reassessed the initial therapeutic approach to evaluate its impact on the therapeutic management.
Results: PSMA-PET/MRI correctly identified prostate cancer in 119 of 122 patients (97.5%). Eighty-one patients were treated with RP and pelvic lymphadenectomy. The accuracy for T staging was 82.5% [95% confidence interval (CI), 73-90; P < 0.001], for T2 stage was 85% (95% CI, 71-94; P < 0.001), for T3a stage was 79% (95% CI, 43-85; P < 0.001), for T3b stage was 94% (95% CI, 73-100; P < 0.001), and for N1 stage was 93% (95% CI, 84-98; P < 0.001). PSMA-PET/MRI changed the therapeutic strategy in 28.7% of the patients with either the onset of systemic therapy/radiotherapy (n = 16) or active surveillance (n = 19).
Conclusions: PSMA-PET/MRI can provide an accurate staging of newly diagnosed prostate cancer. In addition, treatment strategies were changed in almost a third of the patients due to the information of this hybrid imaging technique. (C) 2018 AACR.
Schlagwörter
Aged; Biomarkers, Tumor; Biopsy; Humans; Immunohistochemistry; Ligands; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imagingmethodsstandards; Male; Membrane Glycoproteins; Middle Aged; Neoplasm Staging; Organometallic Compounds; Positron-Emission Tomographymethodsstandards; Prostatic Neoplasmsdiagnosismetabolismtherapy; Pyrrolidines; Radiopharmaceuticals
Dokumententyp
Originalarbeit
ISSN/eISSN
1078-0432 - 1557-3265
10.1158/1078-0432.CCR-18-0768
WoS ID
PubMed ID